SCHEMBL257704

SCHEMBL257704

CCOCc1nn2c(-c3ccc(F)cc3)cc(NCCO)nc2c1-c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
PKM P14618 1/20 0.42
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MKNK1 Q9BUB5 2/20 0.36
THRB P10828 3/20 0.35
FYN P06241 1/20 0.35
CYP1A2 P05177 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
MAPK14 Q16539 2/20 0.32
LMNA P02545 1/20 0.32
USP2 O75604 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020688 0.86 PKM (0.41) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL256953 0.82 MAPT (0.41) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL10071867 0.81 PKM (0.54) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL15020888 0.75 FPR2 (0.42) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL15020887 0.75 FPR2 (0.42) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL15020809 0.73 PKM (0.51) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL15020997 0.73 PKM (0.47) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL15020739 0.73 PKM (0.44) MAPTALDH1A1KDM4EPKMHPGD
SCHEMBL256948 0.71 ARF6 (0.44)
SCHEMBL257503 0.70 ALDH1A1 (0.50) MAPTALDH1A1KDM4EPKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885ALDH1A1 2139/4885KDM4E 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.